# Seragy Secures €12 Million Financing For Neurodegenerative Biomarkers

> Seragy's €12 million funding accelerates biomarker tech for neurodegenerative diseases.
- Title: Seragy Secures €12 Million Financing For Neurodegenerative…
- Summary: Seragy's €12 million funding accelerates biomarker tech for neurodegenerative diseases. Seragy Holding secured €12 million to advance its SeRAS platform for…
- Keywords: seragy, searas, neurodegenerative diseases, protein aggregation, commerzbank, mbg, state of lower saxony, alzheimers, parkinsons, amyotrophic lateral sclerosis, startups, business
- Source: Pulse 2.0 — https://pulse2.com/seragy-secures-e12-million-financing-to-advance-biomarkers-for-neurodegenerative-diseases
- Author: Amit Chowdhry
- Published: 2026-10-19T16:25:56+00:00
- Read time: 1 min
- Topics: seragy, searas, neurodegenerative diseases, protein aggregation, commerzbank, mbg, state of lower saxony, alzheimers, parkinsons, amyotrophic lateral sclerosis, startups, business
## Financing secured
Seragy Holding has secured €12 million in financing to accelerate development of its proprietary SeRAS platform and expand laboratory capabilities for neurodegenerative diseases and other conditions driven by pathological protein aggregation.
## Investors include
The financing is backed by Commerzbank, the Mittelständische Beteiligungsgesellschaft, or MBG, and the State of Lower Saxony.
## SeRAS platform
Seragy develops quantitative biomarkers for proteopathies including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis.
## Technology details
SeRAS combines seeding-based biochemistry with high-sensitivity optics, automated data analysis, software algorithms, and micromechanical components.
## Applications
Seragy plans to support pharmaceutical and biotechnology companies from early drug discovery through preclinical and clinical development.
## Key takeaway

Seragy Holding secured €12 million to advance its SeRAS platform for measuring protein aggregation in neurodegenerative diseases.